Colchicine as Rescue Treatment in Two Pediatrics Patients With Chronic Recurrent Multifocal Osteomyelitis (CRMO).

Chronic recurrent multifocal osteomyelitis (CRMO) is a rare idiopathic autoinflammatory bone disease consisted on non-infective inflammation of bones. Diagnostic approach is challenging and required exclusion of other causes such as malignancies or infections. Non-steroid anti-inflammatory drugs (NSAIDs) and corticosteroids are usually applied as first-line therapy in CRMO patients; however, some cases require more intensive therapy with second-line agents to control disease activity. We hereby describe the use of colchicine as a non-conventional second-line disease-modifying anti-rheumatic drug in two pediatric patients with CRMO refractory to NSAIDs and corticosteroids. Our data indicate that colchicine might prove an important area for future research as a potential therapeutic option with easy administration, low cost and a good safety profile, in CRMO patients refractory to first-line therapy.